In this study, we construct a novel tumor vaccine (SZU251 + MUC1 + Al) with three components: a small-molecule TLR7 agonist synthesized for the first time (SZU251), an MUC1-related peptide (MUC1), and an aluminum adjuvant (Al). This evidence concerns the gene TLR7 and neoplasm.